SUMMIT: Tirzepatide and heart failure with preserved ejection fraction SUMMIT (Packer et al., NEJM 2024, NEJMoa2410027, PMID 39555826) randomized 731 patients with heart failure with preserved ejection fraction (HFpEF) and a BMI 30 to tirzepatide up to 15 mg/week or placebo, with a median follow-up of 104 weeks
Is AOD 9604 FDA-Approved
The most comprehensive study, published in BioMed Research International (2021), found that 5-amino-1MQ treatment "reverses diet-induced obesity and related T2D" in obese mice
Mobile-first players frequently look for a polished hub such as a well-designed stake app that consolidates quick search, one-tap favorites, biometric login, granular notification controls, and battery-efficient streaming, because convenient navigation and low data usage can make the difference between short, casual sessions and deeper, more focused play